#Japan #Novo Nordisk #Obesity Care #Kasugai #Kasugai City

Introduction

Novo Nordisk Pharma and Kasugai City in Aichi Prefecture are pioneering a revolutionary approach to weight management, establishing a new model aimed at addressing obesity. In a historic partnership, they have implemented a program to connect citizens struggling with severe obesity (defined by a BMI over 35) with specialized medical support, marking the first such initiative in Japan.

Background

Obesity is a medically recognized disease that often doesn't receive proper attention due to prevailing misconceptions about personal responsibility. Such misunderstandings can deter individuals from seeking necessary medical intervention. By ensuring proper treatment through professional guidance, the initiative not only targets obesity itself but also aims to ameliorate associated health risks. The importance of structured obesity management has been emphasized in government policies, including the recently outlined "Basic Policy on Economic and Fiscal Management and Reform 2026," which promotes proactive preventive medical practices and early intervention strategies aimed at behavior modification.

Kasugai City faces an increasing prevalence of metabolic syndrome, estimating about 2,500 residents to have severe obesity as of 2023. This statistic underscores the pressing need for an effective healthcare navigation system to connect these individuals with appropriate medical services.

To address these challenges, Novo Nordisk Pharma and Kasugai City signed a comprehensive partnership agreement in October 2024 to improve the management of obesity and extend citizens' healthy lifespans. The partnership focuses on enhancing public awareness about obesity, disseminating correct health information, and promoting behavioral changes towards lifestyle improvements.

Key Initiatives

The pilot program, which ran from October 2024, utilized health examinations from the Kasugai General Health Medical Center to identify residents with a BMI over 35 who hadn’t yet sought medical care. Health professionals directly engaged with these citizens to encourage consultations with specialist clinics, validating the connection process between health screenings and treatment.

The program implemented three core strategies for encouraging treatment:
1. Health Guidance at City Health Centers: Direct recommendations made during standard health check-ups.
2. Mass Mail Notifications: Comprehensive outreach to all eligible individuals promoting healthcare visits.
3. Referrals from Family Doctors to Specialists: Facilitation of access to specialized medical services.

Additionally, visually engaging brochures were produced to help individuals understand their health status and appreciate the importance of seeking professional care. These materials aim to foster a recognition of obesity as a medical condition, thereby reducing the emotional barriers that hinder treatment seeking.

Results

This initiative represents the first successful implementation of a smooth transition from health check-ups to treatment in Japan. According to survey responses from participants, 67% expressed a desire to consult with healthcare providers.
Among 104 individuals who received obesity guidance, 44 who lacked a family doctor were encouraged to seek further medical help, resulting in seven referrals to specialist clinics where all were subsequently diagnosed with obesity.

Comments from Officials

Naoki Ishiguro, the Mayor of Kasugai, emphasized the city's commitment to health enhancement under the "Kasugai Health Project 2035". He regards this obesity treatment initiative as groundbreaking, poised to transform how residents receive healthcare support. Ishiguro highlighted the necessity of collaboration with medical associations and relevant entities to foster a community where residents thrive in health and happiness.

Ryo Kato, the Head of Healthcare Policy and External Affairs at Novo Nordisk Pharma, remarked on the urgent need to create environments conducive to early diagnosis and treatment of obesity as a chronic disease. The success of the outreach model in Kasugai could set a precedent for similar initiatives across Japan.

Future Developments

Looking ahead, the partnership aims to refine outreach methods used to initiate consultations, deepen collaborations with medical facilities, and develop long-term evaluation metrics and follow-up systems. These efforts will collectively strive toward establishing a sustainable community model for obesity management.

For further details, visitors can access the report on Kasugai City's obesity management project via the official website.

Conclusion

The collaborative efforts between Novo Nordisk and Kasugai City represent a significant step forward in public health policies regarding obesity management in Japan. The successful pilot program not only addresses immediate health concerns but also lays the groundwork for a community that prioritizes preventive health measures and fosters a culture of well-being.